Pacific Biosciences of California, Inc.
PACB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $385,080 | $372,201 | $350,292 | $517,888 |
| - Cash | $56,467 | $54,803 | $58,507 | $55,370 |
| + Debt | $700,080 | $699,221 | $699,111 | $672,434 |
| Enterprise Value | $1,028,693 | $1,016,619 | $990,896 | $1,134,952 |
| Revenue | $38,441 | $39,766 | $37,153 | $39,224 |
| % Growth | -3.3% | 7% | -5.3% | – |
| Gross Profit | $15,901 | $14,684 | -$1,371 | $10,058 |
| % Margin | 41.4% | 36.9% | -3.7% | 25.6% |
| EBITDA | -$32,397 | -$35,575 | -$51,861 | $16,393 |
| % Margin | -84.3% | -89.5% | -139.6% | 41.8% |
| Net Income | -$38,000 | -$41,930 | -$426,075 | $2,371 |
| % Margin | -98.9% | -105.4% | -1,146.8% | 6% |
| EPS Diluted | -0.13 | -0.14 | -1.44 | 0.008 |
| % Growth | 7.1% | 90.3% | -18,801.3% | – |
| Operating Cash Flow | -$18,707 | -$29,377 | -$44,056 | -$30,650 |
| Capital Expenditures | $86 | -$550 | -$6,389 | -$1,617 |
| Free Cash Flow | -$18,621 | -$29,927 | -$50,445 | -$32,267 |